Precigen, Inc. - Common Stock (PGEN)

Competitors to Precigen, Inc. - Common Stock (PGEN)

Bluebird Bio, Inc. 

Bluebird Bio is known for its work in gene therapies for genetic diseases and cancer, competing directly with Precigen in these therapeutic areas. Both companies aim to develop innovative cell and gene therapies; however, Bluebird has a more mature product pipeline with FDA-approved therapies, providing it a stronger foothold in the market and greater investor confidence when compared to Precigen.

CRISPR Therapeutics AG 

CRISPR Therapeutics focuses on gene editing technology using CRISPR/Cas9 to develop transformative treatments, similar to Precigen's work in gene therapies. Both companies target genetic disorders and cancer treatments, but CRISPR’s more established technology platform and its pipeline of therapies provide it a competitive advantage in terms of clinical trial success rates and strategic partnerships.

Intellia Therapeutics, Inc. 

Intellia Therapeutics is a leader in the application of CRISPR technology for gene editing, competing with Precigen in the development of curative therapies for genetic diseases. Both companies are pushing the boundaries of genetic medicine, but Intellia has a strong pipeline, including partnerships with major pharmaceutical companies, which gives it a competitive advantage in terms of funding and research capabilities compared to Precigen.

Moderna, Inc. 

Moderna, Inc. specializes in mRNA technology, which has been instrumental in the development of their COVID-19 vaccine. Precigen, focusing on gene and cell therapies, competes with Moderna in the realm of innovative therapeutic approaches to diseases. Both companies are engaged in cutting-edge research and clinical trials, with Moderna benefiting from its established reputation and resources in mRNA therapeutics, giving it a competitive edge in rapid vaccine development and potential therapeutic solutions.

Sangamo Therapeutics, Inc. 

Sangamo Therapeutics utilizes its proprietary ZFP (zinc finger protein) technology for genome editing, competing with Precigen's gene therapy offerings. The primary competition lies in their differing approaches to gene editing and therapeutic development; while Precigen focuses on a broader array of therapies, Sangamo's niche in targeted genomic modifications gives it unique advantages in certain markets, although its portfolio is not as expansive.